- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
Jonathan Abbas, MD, compares the safety and effectiveness of different targeted agents and considerations when selecting a frontline regimen for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
The discussants focused on decision-making for selecting optimal frontline Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) treatment, balancing efficacy and safety. Dr Abbas emphasized assessing ponatinib candidacy early on, given its higher potency and unique adverse effect profile requiring extensive cardiac screening. He noted that if patients cannot receive ponatinib, the approach may shift toward allogeneic stem cell transplant. Dr Ebot-Tar discussed payer strategies to facilitate timely access without administrative barriers. She highlighted the value of provider input on pharmacy and therapeutics committees when making coverage determinations for specialized disease states like Ph+ ALL.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
